Our Pipeline

Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings.

Pipeline 122019v3 Refractory Status Epilepticus CDKL5 Deficiency Disorder PCDH19-Related Epilepsy

Clinical Trial Information

Ganaxolone is being developed in intravenous (IV) and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.

Marinus is currently conducting studies in CDKL5 deficiency disorder, PCDH19-related epilepsy, and refractory status epilepticus.

Learn More



pipeline divider 2

icon patient resources

Explore Patient Resources

Find helpful information and patient networks, as well as clinical trial opportunities.

View Patient Resources

icon bibilography


Find publications referencing ganaxolone and its affect on seizures and neuropsychiatric disorders.